drugset / Trial / NCT00790803

Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema

NCT00790803

Completed 5 enrolled Wake Forest University
NaSingle-groupOpen-labelTreatment

Summary

According to a recent estimate more than 280,000 people in the United States are affected by uveitis each year. This report, also estimated that uveitis is the reason for 30,000 new cases of blindness/year and up to 10 percent of all cases of blindness. The purpose of this trial is to determine the effectiveness of VEGF blockade with intravitreal pegaptanib in patients with uveitic CME.

Timeline

Start
2009-03
Primary completion
2011-11
Completion
2012-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer 0.3 mg Intravitreal